Literature DB >> 23492989

Five-year follow-up of drug-eluting stents implantation vs minimally invasive direct coronary artery bypass for left anterior descending artery disease: a propensity score analysis.

Pierre Yves Etienne1, William D'hoore, Spiridon Papadatos, Yves Mairy, Gebrine El Khoury, Philippe Noirhomme, Claude Hanet, David Glineur.   

Abstract

OBJECTIVES: The spread of drug-eluting stents (DES) has reduced the incidence of early restenosis following percutaneous coronary interventions (PCI). Meanwhile, development of minimally invasive coronary artery bypass surgery (MIDCAB) has offered a valuable alternative to conventional sternotomy with preservation of the benefit of the internal mammary artery use. Therefore, the revascularization of the left anterior descending (LAD) artery is suitable for both techniques. However, few data with long-term comparison of these two techniques exist.
METHODS: Prospective data were collected for 456 patients undergoing isolated LAD revascularization between 1997 and 2011. Two hundred and sixty patients were treated with MIDCAB and 196 with first-generation DES implantation. A propensity score model was created to adjust for 19 relevant confounding variables. Primary and secondary end-points were, respectively, 5-year survival and freedom from major adverse cerebro-cardiovascular events (MACCE).
RESULTS: Both groups were similar in age, EuroSCORE and mean duration of follow-up. Five-year survival was similar after MIDCAB or DES (hazard ratio (HR): 0.95; P = 0.89). Freedom from MACCE was significantly in favour of the MIDCAB group (HR: 0.32, P < 0.0001), mainly triggered by high subsequent need for revascularization of the targeted vessel in the DES group (HR: 0.17, P < 0.0001).
CONCLUSIONS: MIDCAB and DES implantation showed similar rates of survival but despite an expected lower rate of reintervention on the targeted vessel with DES use, a highly significant higher MACCE rate was observed in the PCI group at 5-year follow-up.

Entities:  

Keywords:  Bypass; Coronary disease; Internal thoracic artery; Stent; Surgery

Mesh:

Year:  2013        PMID: 23492989     DOI: 10.1093/ejcts/ezt137

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  5 in total

Review 1.  Meta-analysis of minimally invasive coronary artery bypass versus drug-eluting stents for isolated left anterior descending coronary artery disease.

Authors:  Ralf E Harskamp; Judson B Williams; Michael E Halkos; Renato D Lopes; Jan G P Tijssen; T Bruce Ferguson; Robbert J de Winter
Journal:  J Thorac Cardiovasc Surg       Date:  2014-03-20       Impact factor: 5.209

Review 2.  Minimally invasive surgery or stenting for left anterior descending artery disease - meta-analysis.

Authors:  Monica Gianoli; Anne R de Jong; Kirolos A Jacob; Hanae F Namba; Niels P van der Kaaij; Pim van der Harst; Willem J L Suyker
Journal:  Int J Cardiol Heart Vasc       Date:  2022-05-10

3.  Frequency and Predictors of Internal Mammary Artery Graft Failure and Subsequent Clinical Outcomes: Insights From the Project of Ex-vivo Vein Graft Engineering via Transfection (PREVENT) IV Trial.

Authors:  Ralf E Harskamp; John H Alexander; T Bruce Ferguson; Rebecca Hager; Michael J Mack; Brian Englum; Daniel Wojdyla; Phillip J Schulte; Nicholas T Kouchoukos; Robbert J de Winter; C Michael Gibson; Eric D Peterson; Robert A Harrington; Peter K Smith; Renato D Lopes
Journal:  Circulation       Date:  2015-12-08       Impact factor: 29.690

Review 4.  Targeting Non-coding RNA in Vascular Biology and Disease.

Authors:  John Hung; Vladislav Miscianinov; Judith C Sluimer; David E Newby; Andrew H Baker
Journal:  Front Physiol       Date:  2018-11-22       Impact factor: 4.566

5.  Relationship between left coronary artery bifurcation angle and restenosis after stenting of the proximal left anterior descending artery.

Authors:  Takao Konishi; Tadashi Yamamoto; Naohiro Funayama; Hiroshi Nishihara; Daisuke Hotta
Journal:  Coron Artery Dis       Date:  2016-09       Impact factor: 1.439

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.